Planning for Production Scale
The development of an industrial process should begin right at the start – when the product is still at the preclinical stage.
Daniel Maier |
The design and development of the optimal production process is a big challenge – and it’s rare that upscaling runs smoothly. The growing demand of monoclonal antibodies (mAbs) requires efforts to increase production capacities and product titers. Experience shows that an ideal up-scaling process tends to rely on the field of hydrodynamics and process engineering; numerous indicators and values are needed to develop the right strategy. Many parameters, such as mixing time and the volumetric mass transfer coefficient (kLa), however, cannot be transferred in a linear manner, so successful up-scaling always involves compromises.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine